WorldCat Identities

Cottin, Vincent

Overview
Works: 57 works in 75 publications in 2 languages and 407 library holdings
Roles: Editor, Other, Contributor, Thesis advisor, Author
Publication Timeline
.
Most widely held works by Vincent Cottin
Orphan lung diseases : a clinical guide to rare lung disease by Vincent Cottin( )

15 editions published in 2015 in English and held by 265 WorldCat member libraries worldwide

Focusing on clinical practice, this book explores the less common diseases affecting the airways, systematic disorders with lung involvement, interstitial lung diseases and many other orphan conditions of the lungs. It helps the reader to diagnose and manage these rare orphan diseases. Orphan Lung Diseases: A Clinical Guide to Rare Lung Disease is a practical, informative book written by a team of international authors with much experience in rare pulmonary diseases. Orphan Lung Diseases: A Clinical Guide to Rare Lung Disease provides synthesized and easily accessible information about the main orphan lung diseases, to aid clinicians in charge of patients with rare disease, or who consider the diagnosis of a rare disease in their patient
Traité de médecine by L Guillevin( Book )

1 edition published in 2020 in French and held by 35 WorldCat member libraries worldwide

Le traité de référence en langue française depuis plus de 35 ans : « Un socle indestructible des connaissances médicales ». Un guide pragmatique rendant compte de l'évolution permanente de l'enrichissement des connaissances médicales sans que la complexité l'emporte sur la clarté et obscurcisse la réflexion du praticien. Cinq éditions, plus de 60 000 exemplaires vendus, le Traité de Médecine créé par le Professeur Pierre Godeau a accompagné des générations de médecins, généralistes ou spécialistes, débutants ou en exercice. L'intégralité du Traité représente plus de 900 chapitres, plus de 1 000 auteurs reconnus pour leur expertise dans le domaine et 6 000 pages, pour : - transmettre les connaissances médicales, validées scientifiquement, affermies par l'épreuve du temps et l'expérience clinique des auteurs, nécessaires à tous les médecins, en exercice ou en formation. - offrir aux lecteurs les données essentielles de chaque spécialité pour assurer la meilleure « prise en charge globale des patients. - renseigner rapidement sur une maladie, un symptôme, un test de laboratoire et actualiser ses connaissances. Le Volume 2, tout en quadrichromie, c'est 320 chapitres rédigés par 450 auteurs, illustrés de 900 figures et 500 tableaux. Les sections présentes dans ce troisième volume sont : Pneumologie - Rhumatologie - Génétique et maladies métaboloques - Ophtalmologie - Oto-Rhino-Laryngologie - Pathologie orale et maxillofaciale - Gynécologie - Néphrologie - Thérapeutique - Anesthésie, Réanimation et Médecine péri-opératoire - Maladies infectieuses (éditeur)
Santé publique by Thomas Bénet( )

1 edition published in 2012 in French and held by 5 WorldCat member libraries worldwide

Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis by Vincent Grobost( Book )

2 editions published in 2014 in English and held by 4 WorldCat member libraries worldwide

Pulmonary Langerhans cell histiocytosis is a rare disorder characterised by granulomatous proliferation of CD1a-positive histiocytes forming granulomas within the lung parenchyma, strongly associated with tobacco smoking, and which may result in chronic respiratory failure. Smoking cessation is considered critical to management, however with variable effect on outcome. No drug therapy has been validated. Cladribine (chlorodeoxyadenosine, 2-CdA) down-regulates the proliferation of histiocytes, cases of Pulmonary Langerhans cell histiocytosis. We retrospective studied five patients (aged 37-55 years, 3 females) with pulmonary Langerhans cell histiocytosis, who received 3 to 4 courses of cladribine therapy as a single agent (0.1 mg/kg per day for 5 consecutive days at monthly intervals). One patient was treated twice because of relapse at one year. Indication for treatment was progressive pulmonary disease with obstructive ventilatory pattern despite smoking cessation and/or corticosteroid therapy. Patients received oral trimethoprim/sulfamethoxazole and valaciclovir to prevent opportunistic infections. Patients gave written consent to receive off-label cladribine in the absence of validated treatment. Functional class dyspnea improved with cladribine therapy in 4 out of 6 cases, and forced expiratory volume in one second increased in all cases by a mean of 387 ml (100-920ml), contrasting with steadily decline prior to treatment. Chest HRCT features improved with cladribine therapy in four of five patients. Hemodynamic improvement was observed in one patient with precapillary pulmonary hypertension. Result suggested greater treatment effect in subjects with nodular lung lesions and/or thick-walled cysts at chest HRCT, with diffuse hypermetabolism of lung lesions at PET scan, and with progressive disease despite smoking cessation. Infectious pneumonia developed in one patient, with later grade 4 neutrocytopenia without infection. Interpretation of data was limited by the retrospective, uncontrolled design, and the small sample size. Cladribine as a single agent may be an effective therapy in patients with progressive pulmonary Langerhans cell histiocytosis
Alveolar Hemorrhage in Vasculitis: Primary and Secondary( )

2 editions published between 2011 and 2018 in English and held by 4 WorldCat member libraries worldwide

Comparaison et impact des comorbidités dans la fibrose pulmonaire idiopathique et le syndrome emphysème-fibrose by Clément Deudon( Book )

2 editions published in 2016 in French and held by 3 WorldCat member libraries worldwide

Plusieurs études ont montré la fréquence élevée de comorbidités et leur impact dans la fibrose pulmonaire idiopathique (FPI). Ces données ne sont pas connues dans le syndrome emphysème-fibrose (SEF). Le but de notre étude était de comparer la fréquence des comorbidités dans la FPI et le SEF, et d'analyser leur impact sur la mortalité. Nous avons inclus dans l'analyse 85 patients ayant un SEF diagnostiqué entre 01/2006 et 12/2012 (80 hommes, âge moyen 69,4 ±8,5 ans) et 119 patients ayant une FPI diagnostiquée entre 01/2011 et 12/2014 (103 hommes, âge moyen 71,2 ±7,7 ans). Les plus fréquentes comorbidités chez les patients atteints de SEF étaient les comorbidités cardio-vasculaires (CV) (54,1%), en particulier la dysfonction ventriculaire droite (DVD) (71,6%). Durant le suivi, les plus fréquentes comorbidités observées chez les patients atteints de SEF étaient l'hypertension pulmonaire (HTP) (52,9%), les comorbidités CV (16,5%), et le cancer bronchique (14,1%). La DVD était significativement plus fréquente dans le SEF que dans la FPI (71,6% vs. 25,6% respectivement, p<0,001), ainsi que l'HTP durant le suivi (52% vs. 10,2%, p<0,001), le cancer bronchique (14,1% vs. 5,9%, p=0,05), et les coronaropathies (10,6% vs. 3,4%, p=0,04). Un antécédent de comorbidité augmentait significativement la mortalité dans le SEF (RR 2,46, 95%IC 1,32-4,59), en particulier un antécédent de comorbidité CV (RR 2,81, 95%IC 1,39-5,70) ou une HTP (RR 2,45, 95%IC 1,27-4,71). Il n'existait pas de différence significative entre les deux cohortes pour le reflux gastro-oesophagien et les apnées du sommeil. En conclusion, le SEF est associé à des comorbidités fréquentes et distinctes de la FPI, en particulier les comorbidités CV et l'HTP, conduisant à envisager leur dépistage
Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events by Ulrich Costabel( )

2 editions published in 2014 in English and held by 3 WorldCat member libraries worldwide

Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free survival. Although generally well tolerated, a minority of patients discontinue therapy due to gastrointestinal and skin-related adverse events (AEs). This review summarizes recommendations based on existing guidelines, research evidence, and consensus opinions of expert authors, with the aim of providing practicing physicians with the specific clinical information needed to educate the patient and better manage pirfenidone-related AEs with continued pirfenidone treatment. The main recommendations to help prevent and/or mitigate gastrointestinal and skin-related AEs include taking pirfenidone during (or after) a meal, avoiding sun exposure, wearing protective clothing, and applying a broad-spectrum sunscreen with high ultraviolet (UV) A and UVB protection. These measures can help optimize AE management, which is key to maintaining patients on an optimal treatment dose
Le syndrome emphysème-fibrose : aspects évolutifs, pronostic et complications by Kaïs Ahmad( )

1 edition published in 2013 in French and held by 2 WorldCat member libraries worldwide

TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients by On behalf of TOSCA consortium and TOSCA investigators( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Presence of Kidney Disease as an Outcome Predictor in Patients with Pulmonary Arterial Hypertension by Laurent Bitker( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review by Fabrizio Luppi( )

1 edition published in 2015 in English and held by 2 WorldCat member libraries worldwide

A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT by Stéphane Jouneau( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

Lung Biopsy in Interstitial Lung Diseases: There Is More than One Way to Cook an Egg by Mouhamad Nasser( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

Dysregulation of the endothelin pathway in lymphangioleiomyomatosis with no direct effect on cell proliferation and migration by Nader Chebib( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

Centrilobular emphysema combined with pulmonary fibrosis results in improved survival: a response by Vincent Cottin( )

1 edition published in 2011 in English and held by 2 WorldCat member libraries worldwide

Pilot experience of multidisciplinary team discussion dedicated to inherited pulmonary fibrosis by Raphael Borie( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

Interstitial lung disease associated with systemic sclerosis (SSc-ILD) by Vincent Cottin( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

Presenting the Board of Respiration : Vincent Cottin by Vincent Cottin( )

1 edition published in 2020 in English and held by 2 WorldCat member libraries worldwide

Whole exome sequencing in three families segregating a pediatric case of sarcoidosis by In the frame of GSF (Groupe Sarcoïdose France)( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study by Abdellatif Tazi( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  General Special  
Audience level: 0.61 (from 0.51 for Santé pub ... to 0.97 for Orphan lun ...)

Orphan lung diseases : a clinical guide to rare lung disease
Covers
Alternative Names
Vincent Cottin onderzoeker

Vincent Cottin researcher

Languages
English (33)

French (5)